The impact of dapagliflozin on blood glucose and cognitive function in type 2 diabetes patients with ischemic stroke
Objective To explore the effects of dapagliflozin on blood glucose and cognitive function in patients with type 2 diabetes mellitus (T2DM) and ischemic stroke (IS).Methods Patients with T2DM and IS admitted to the Department of Neurology,Beijing Tiantan Hospital,Capital Medical University from January 2022 to January 2023 were collected and randomly divided into dapagliflozin group (conventional treatment+dapagliflozin) and control group (conventional treatment+metformin) for 6 months of continuous treatment.Blood glucose control levels and fluctuations were compared before and after treatment.The Montreal Cognitive Assessment (MoCA) was used to evaluate cognitive function before and after treatment.Results A total of 100 patients were included in the study,50 in the dapagliflozin group and 50 in the control group.After 6 months of treatment,blood glucose levels and fluctuations decreased in both groups (P<0.05),but were lower in the dapagliflozin group (P<0.05).Regarding cognitive function,MoCA scores increased in both groups,with the dapagliflozin group showing higher scores,especially in visuospatial executive function and delayed recall (P<0.05).Conclusion Dapagliflozin can effectively control blood glucose levels and fluctuations in T2DM patients with IS,and improve cognitive function,particularly in visuospatial executive function and delayed recall.
DapagliflozinType 2 diabetesIschemic strokeBlood glucoseCognitive function
NETL
NSTL
万方数据
